Evidence map›Paper›PMID 28928972›Full record

ArticleBiomedical reports2017

Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and

Carolina Leite, Lucas Delmonico, Gilda Alves, Romario José Gomes, Mariana Rodrigues Martino, Aline Rodrigues da Silva, Aline Dos Santos Moreira, Maria Christina Maioli, Luciano Rios Scherrer, Elenice Ferreira Bastos and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Biomedical reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Carolina LeiteHaematology Service, Pedro Ernesto University Hospital, Rio de Janeiro 20550-170, Brazil.
Lucas DelmonicoCirculating Biomarkers Laboratory, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Gilda AlvesCirculating Biomarkers Laboratory, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Romario José GomesCirculating Biomarkers Laboratory, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Mariana Rodrigues MartinoCirculating Biomarkers Laboratory, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Aline Rodrigues da SilvaCirculating Biomarkers Laboratory, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Aline Dos Santos MoreiraBioinformatics and Functional Genomic Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.
Maria Christina MaioliHaematology Service, Pedro Ernesto University Hospital, Rio de Janeiro 20550-170, Brazil.
Luciano Rios ScherrerDepartment of Engineering and Production, Kennedy Faculty, Belo Horizonte 31535-040, Brazil.
Elenice Ferreira BastosDepartment of Medical Genetic, Fernandes Figueira Institute, Oswaldo Cruz Foundation, Rio de Janeiro 22250-020, Brazil.
Roberto IrineuPedro II School, Realengo II Campus, Rio de Janeiro 21710-261, Brazil.
Maria Helena OrnellasCirculating Biomarkers Laboratory, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
Universidade do Estado do Rio de Janeiro · BRFundação Oswaldo Cruz · BRHospital Universitário Pedro Ernesto · BRColégio Pedro II · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis, different degrees of cellular dysplasia, and increased risk of progression to acute myeloid leukemia. International Prognostic Scoring System is the gold standard for MDS classification; however, patients exhibiting different clinical behaviors often coexist in the same group, indicating that the currently available scoring systems are insufficient. The genes that have recently been identified as mutated in MDS, including additional sex combs like 1, transcriptional regulator (

Indexed as

additional sex combs like 1GTPaseGTPase/NRAS proto-oncogenemyelodysplastic syndrometranscriptional regulatortumor protein p53, and KRAS proto-oncogene

Identifiers

PMID28928972
PMCPMC5590036
OpenAlexW2744524986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.